Analysis of Clinical Factors Impacting Imatinib Trough Concentrations in Chinese Patients With Gastrointestinal Stromal Tumors: A Real-World Study
{{output}}
Background: Imatinib mesylate (IM) is the first-line treatment for gastrointestinal stromal tumors (GISTs) and significantly improves patient outcomes. However, high inter-patient variability in imatinib plasma exposure leads to ... ...
